Table 1.
Baseline characteristics stratified by the primary endpoint
| Variables | Total (n = 8050) | Non-MACEs (n = 7376) | MACEs (n = 674) | P value |
|---|---|---|---|---|
| Age, years | 58.4 ± 10.2 | 58.3 ± 10.1 | 60.0 ± 10.7 | < 0.001 |
| Male | 6166 (76.6) | 5640 (76.5) | 526 (81.3) | 0.355 |
| Body mass index, kg/m2 | 25.9 ± 3.2 | 25.9 ± 3.2 | 25.9 ± 3.3 | 0.830 |
| Previous history | ||||
| DM | 2444 (30.4) | 2194 (29.7) | 250 (37.1) | < 0.001 |
| Hypertension | 5155 (64.0) | 4696 (63.7) | 459 (68.1) | 0.022 |
| Hyperlipidemia | 5400 (67.1) | 4940 (67.0) | 460 (68.2) | 0.500 |
| Current smoking | 4530 (56.3) | 4137 (56.1) | 393 (58.3) | 0.266 |
| Stoke | 834 (10.4) | 750 (10.2) | 84 (12.5) | 0.061 |
| PAD | 620 (7.7) | 550 (7.5) | 70 (10.4) | 0.006 |
| Clinical history | ||||
| Previous PCI | 1922 (23.9) | 1726 (23.4) | 196 (29.1) | 0.001 |
| Previous CABG | 339 (4.2) | 295 (4.0) | 44 (6.5) | 0.002 |
| Previous MI | 1587 (19.7) | 1426 (19.3) | 161 (23.9) | 0.004 |
| Clinical presentation | 0.683 | |||
| ACS | 4598 (57.1) | 4208 (57.0) | 390 (57.9) | |
| CCS | 3452 (42.9) | 3168 (43.0) | 284 (42.1) | |
| Laboratory | ||||
| hsCRP, mg//L | 1.39 (0.73–2.69) | 1.37 (0.73–2.65) | 1.56 (0.84–3.17) | 0.007 |
| HbA1c, % | 6.59 ± 1.19 | 6.58 ± 1.19 | 6.71 ± 1.23 | 0.006 |
| Creatinine, mmol/L | 74.9 ± 15.4 | 74.8 ± 15.2 | 76.9 ± 17.1 | < 0.001 |
| LDL, mmol/L | 2.48 ± 0.91 | 2.48 ± 0.91 | 2.48 ± 0.88 | 0.991 |
| LVEF, % | 63.3 ± 7.0 | 63.5 ± 6.9 | 62.0 ± 7.8 | < 0.001 |
| Discharge therapy | ||||
| Aspirin | 7958 (98.9) | 7293 (98.9) | 665 (98.7) | 0.623 |
| Clopidogrel | 7930 (98.5) | 7263 (98.5) | 667 (99.0) | 0.312 |
| Beat-blocker | 7246 (90.0) | 6647 (90.1) | 559 (82.9) | 0.302 |
| Statins | 7734 (96.1) | 7087 (96.1) | 647 (96.0) | 0.911 |
| Insulin | 968 (12.0) | 868 (11.8) | 100 (14.8) | 0.019 |
| DAPT | 7847 (97.5) | 7188 (97.5) | 659 (97.8) | 0.608 |
| PCI-related data | ||||
| Multivessel disease | 6074 (75.5) | 5494 (74.5) | 580 (86.1) | < 0.001 |
| LM stenosis | 510 (6.3) | 464 (6.3) | 46 (6.8) | 0.586 |
| SYNTAX score | 10.0 (5.5–16.0) | 10.0 (5.0–16.0) | 12.0 (7.0–19.0) | < 0.001 |
| TIMI 0 before PCI | 1288 (16.0) | 1148 (15.6) | 140 (20.8) | < 0.001 |
| Number of stents | 2 (1–2) | 2 (1–2) | 2 (1–2) | 0.117 |
| Target group | < 0.001 | |||
| HsCRP-L/non-DM | 4417 (54.9) | 4105 (55.7) | 312 (46.3) | |
| HsCRP-H/non-DM | 1189 (14.8) | 1077 (14.6) | 112 (16.6) | |
| HsCRP-L/DM | 1898 (23.6) | 1717 (23.3) | 181 (26.9) | |
| HsCRP-H/DM | 546 (6.8) | 477 (6.5) | 89 (13.2) | |
Bolded p-values indicate statistically significant differences
MACEs major adverse cardiovascular events, DM diabetes mellitus, PAD peripheral arterial disease, PCI percutaneous coronary intervention, CABG coronary artery bypass graft, MI myocardial infarction, ACS acute coronary syndrome, CCS chronic coronary syndrome, hsCRP high-sensitivity C-reactive protein, HbA1c glycosylated hemoglobin A1c, LDL low density lipoprotein, LVEF left ventricular ejection fraction, DAPT dual antiplatelet therapy, LM left main.